Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2015-05-04 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
关于回购部分社会公众股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's repurchase of its own shares, detailing the number of shares bought back, prices, and total amount spent. It references the company's share buyback plan approved by shareholders and provides updates on the repurchase activity. The document is short (646 characters) and focuses on share repurchase progress, not a full financial report or earnings release. Therefore, it fits the category of Transaction in Own Shares (POS).
2015-05-04 Chinese
2014年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2014 年度财务决算报告' which translates to '2014 Annual Financial Settlement Report'. It contains detailed financial data including total assets, liabilities, net assets, revenue, profit, cash flow, and comparative figures for 2013 and 2014. The document is comprehensive and includes financial statements and analysis for the full fiscal year 2014. The length is 2076 characters, which is relatively short but the content is substantive financial data rather than a mere announcement or certification. The document is clearly a full annual financial report covering company activity and financial performance for the year 2014. Therefore, it fits the definition of an Annual Report (10-K). FY 2014
2015-04-27 Chinese
2015年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2015 年第一季度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2015 First Quarter Report Full Text." It contains detailed financial data including income, net profit, cash flow, shareholder information, securities investment, and comprehensive financial statements such as consolidated and parent company balance sheets. The presence of quarterly financial data and detailed financial statements indicates this is a quarterly or interim financial report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2015
2015-04-27 Chinese
独立董事对公司相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is a detailed independent directors' opinion report on various company matters including board election, profit distribution, internal control evaluation, audit firm appointment, related party transactions, short-term investments, guarantees, entrusted loans, accounting policy changes, and investment participation. It references compliance with regulatory guidelines and company bylaws, and provides independent opinions on these corporate governance and financial matters. The content is not a full annual report or audit report but rather a governance-related opinion document by independent directors. This fits the category of Board/Management Information (MANG), as it concerns board election and other management-related approvals and opinions. The document length (5397 characters) and detailed content support this classification rather than a brief announcement or a full financial report.
2015-04-27 Chinese
2014年度社会责任报告
Environmental & Social Information Classification · 100% confidence The document is titled "2014 年度社会责任报告" (2014 Annual Social Responsibility Report) and contains detailed sections on the company's social responsibility activities, including protection of shareholder and creditor rights, employee rights, supplier and customer relations, environmental protection, and sustainable development. It references compliance with social responsibility guidelines from the Shenzhen Stock Exchange and includes extensive narrative on environmental, social, and governance (ESG) factors. The document is lengthy (15,000 characters) and contains substantive content rather than just an announcement or summary. This matches the definition of an Environmental & Social Information report (Code: SR).
2015-04-27 Chinese
第五届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the approval of various reports and proposals including the 2014 Supervisory Board Work Report, 2014 Financial Final Report, 2014 Profit Distribution Plan, 2014 Annual Report and Summary, 2015 Q1 Report, 2014 Internal Control Evaluation Report, nomination of new Supervisory Board members, reappointment of the audit firm for 2015, related party transactions, use of idle funds for short-term low-risk investments, and accounting policy changes. The document is a formal announcement of the Supervisory Board's meeting decisions and approvals, not the reports themselves. It references the 2014 Annual Report and 2015 Q1 Report but does not contain the full reports or detailed financial data. The document length is 2773 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of meeting resolutions and approvals related to governance and financial reporting, but not the reports themselves.
2015-04-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.